Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO Income Before Tax

Profit after all operating and non-operating items but before income tax.

Knight Therapeutics Inc.TSX: GUD.TO

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax turns positive

Q1 FY2026 income before tax was CA$14.18M, compared with -CA$399K a year earlier. Trailing-twelve-month income before tax was CA$7.88M.

Context

  • Income before tax amounted to 1.5% of revenue in FY2025, up 0.9 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near CA$14.18M or moves back toward the trailing-twelve-month quarterly average of CA$1.97M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$14.18M+26.4% QoQ
Last fiscal yearDec 2025
-CA$6.7M-426.6% YoY
LTMMar 2026
CA$7.88M-10.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3654.4%——
1 year-426.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

CAD · from the income statement

Latest · FY2025
(6.7M) CAD
Year-over-year change
-426.6%

Income Before Tax vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.4% is the 6th highest of 8, against a peer median of +48.3%.
  • Income before tax amounts to 1.5% of revenue for GUD.TO, versus a peer median of 12.4%.
GUD.TO Competitors
Income Before Tax for GUD.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$22.52M CAD+10.5%—7.1%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$20.21M USD+978.7%+15.0%39.7%
VHI.TOVitalhub Corp.LTM Mar 2026CA$8.02M CAD+48.3%+65.3%6.7%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$7.88M CAD-10.4%—1.5%
TSND.TOTerrAscend Corp.LTM Mar 2026$5.47M USD+111.0%—2.1%
KSI.TOKneat.com, Inc.LTM Mar 2026-CA$8.22M CAD-302.1%—12.4%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-CA$38.87M CAD-329.6%—14.2%
WEED.TOCanopy Growth CorporationLTM Mar 2026-CA$263.45M CAD+55.9%—84.7%
Peer median (excluding GUD.TO) —+48.3%+40.2%12.4%

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue243.48M293.56M328.2M371.3M450.09M
Cost of Revenue128.07M155.5M175.55M196.9M299.35M
Gross Profit115.41M138.06M152.65M174.41M150.74M
Gross Margin47.4%47.0%46.5%47.0%33.5%
Research & Development12.69M14.76M17.55M23.3M28.98M
Selling, General & Admin74.38M88.62M83.69M99.35M123.96M
Operating Expenses128.24M155.12M155.54M167.01M152.94M
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
EBITDA42.59M25.26M40.9M64.38M54.37M
EBITDA Margin17.5%8.6%12.5%17.3%12.1%
Operating Income(5.32M)(2.4M)(2.89M)7.4M(2.2M)
Operating Margin-2.2%-0.8%-0.9%2.0%-0.5%
Interest Income7.38M10.63M12.58M10.41M6.21M
Interest Expense3.62M6.6M12.49M9.22M10.42M
Other Income / Expenses19.52M(2.92M)(19.1M)(5.35M)(4.5M)
Income Before Tax6.69M(43.96M)(21.99M)2.05M(6.7M)
Pre-Tax Margin2.7%-15.0%-6.7%0.6%-1.5%
Income Tax Expense(8.99M)(14.07M)(5.15M)(2.28M)(1.33M)
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Net Margin6.4%-10.2%-5.1%1.2%-1.2%
EPS (Basic)0.13(0.26)(0.16)0.04(0.05)
EPS (Diluted)0.13(0.26)(0.16)0.04(0.05)
Weighted Avg Shares124.48M114.89M107.47M101.04M99.57M
Weighted Avg Shares (Diluted)124.52M114.89M107.47M101.44M99.57M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.